anifrolumab

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

anifrolumab is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 26, 2027 (day precision, medium confidence), tied to trial NCT05138133. The asset is in Phase 3 and currently active not recruiting, studied in Lupus Nephritis. It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-02-26

As disclosedFeb 26, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05138133

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorAstraZeneca

Listed asAZN

Condition(s)Lupus Nephritis

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AZN catalysts